165 related articles for article (PubMed ID: 31357550)
1. Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.
Buiga P; Elson A; Tabernero L; Schwartz JM
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357550
[TBL] [Abstract][Full Text] [Related]
2. Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis.
Buiga P; Elson A; Tabernero L; Schwartz JM
BMC Syst Biol; 2018 Apr; 12(Suppl 1):11. PubMed ID: 29671404
[TBL] [Abstract][Full Text] [Related]
3. Modelling the role of dual specificity phosphatases in herceptin resistant breast cancer cell lines.
Buiga P; Elson A; Tabernero L; Schwartz JM
Comput Biol Chem; 2019 Jun; 80():138-146. PubMed ID: 30952040
[TBL] [Abstract][Full Text] [Related]
4. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
6. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.
Gonzalez-Alonso P; Cristobal I; Zazo S; Martin-Aparicio E; Chamizo C; Madoz-Gurpide J; Rovira A; Eroles P; Lluch A; Albanell J; Rojo F
Curr Med Chem; 2018; 25(17):1976-1998. PubMed ID: 27993109
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
10. Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
Jaques R; Xu S; Matsakas A
Histol Histopathol; 2020 Oct; 35(10):1059-1075. PubMed ID: 32323293
[TBL] [Abstract][Full Text] [Related]
11. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
12. Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H; Kalra S; Kheterpal P; Kumar V; Munshi A
Curr Cancer Drug Targets; 2017; 17(4):344-356. PubMed ID: 27993117
[TBL] [Abstract][Full Text] [Related]
13. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
14. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
Zhang M; Li Z; Liu X
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
16. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
17. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
19. Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.
Yang T; Fu Z; Zhang Y; Wang M; Mao C; Ge W
Biomed Pharmacother; 2020 Sep; 129():110465. PubMed ID: 32887021
[TBL] [Abstract][Full Text] [Related]
20. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
